Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

June 04, 2025 I On May 30, 2025, Conjustar Biologics announced that it’s EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for evaluating the safety and efficacy of SC-102 in patients with advanced or metastatic solid tumors expressing EphA2. Previously, SC-102 has received clinical trial approval in China and has started its clinical trial in Aug 2024, with the first patient enrolled in 2024. SC-101 has demonstrated a good safety profile in its ongoing trial. SC-101 is an innovative peptide-drug conjugate that specifically binds to tumor cells expressing EphA2, releasing a toxic payload to inhibit tumor growth. Mr. Tang Shuyi, the President of Conjustar Biologics, stated “The FDA’s approval of the IND application for SC-102 marks another new milestone in our development of innovative anti-tumor drugs. We will accelerate the clinical development of SC-102, aiming to provide more safe and effective treatment options for cancer patients worldwide.” SOURCE: Tianjin Conjustar Biotechnology

New Delhi: Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication used to increase blood pressure. The Hyderabad-based firm has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL, Gland Pharma said in a statement. Gland Pharma is the exclusive " First-to-File " and is eligible for 180 days of generic drug exclusivity, it stated. The company's product is therapeutically equivalent to La Jolla Pharma LLC's reference listed drug Giapreza . The drug is indicated for increasing the blood pressure in adults with septic or other distributive shock. According to IQVIA, the product had US sales of around USD 58 million for the 12 months ending March 2025. Gland Pharma shares on Wednesday ended 1.88 per cent up at Rs 1,623.70 apiece on BSE. PTI

Hyderabad: Injectables developer Gland Pharma Q4 FY24-25 revenue from operations reported a year-on-year decline of 7 per cent to ₹1,424 crore. While the quarter’s profit margin remained unchanged at 13 per cent against the corresponding period, the Profit After Tax (PAT) reported a decline of 3 per cent YoY and 9 per cent QoQ to ₹186 crore, down from ₹192 crore recorded in the corresponding period. On both quarter and annual basis, the Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) contracted by 3 per cent to ₹ 347 crore. For the full financial year, the company's revenue reported a margin dip of 1 per cent to ₹5,616 crore while its net profit plummeted by 10 per cent to ₹698.5 crore, down from ₹772.5 crore recorded in the previous fiscal. During the period, the company's profit margin contracted by 2 percentage points to 12 per cent. In FY25, the US business reported muted revenue growth while the revenue from Europe, India and Rest of World declined by 2 per cent, 11 per cent and 4 per cent, respectively. Of the total fiscal earnings, revenue from Gland base business declined by 1 per cent to ₹4,124 crore, while the net profit stood at ₹1,086 crore at a stable margin of 26 per cent. On a regional basis Gland’s base business revenue in the US remained flat, standing at ₹2,976 crore whereas its revenue from India contracted by 11 per cent to ₹248 crore. “FY25 was a year of strategic realignment and investment in future growth. Through the year, we mitigated many challenges and strengthened the core by advancing key pillars of manufacturing, quality, and R&D,” said Srinivas Sadu, Executive Chairman, Gland Pharma. During the period, it launched 31 molecules, including “four new molecules namely Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), in Q4 FY25. Gland Pharma also launched its first partnered GLP-1, Liraglutide, in Q4 FY25 and is working to expand its production capacity to 140 million units, up from the current 40 million units As per the company release, discussions with Henlius are progressing well and are expecting revenue generation from the collaboration with Dr Reddy’s in the ongoing fiscal. “Our progress in biologics CDMO and collaborations with leading partners reflect our intent to diversify and grow beyond traditional segments. We remain firmly focused on executing the Cenexi turnaround and leveraging targeted M&A to drive long-term, sustainable value for all stakeholders,” Sadu noted. Outlining the company’s future plans the CEO said, “Our approach involves expanding our core business into new emerging markets, building complex injectables pipeline and through our robust in-house research and development efforts.” Following the announcement of Gland quarter results, the board has recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. By Online Bureau ,